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I NTRO D U C TIO N
Pyrenochaeta romeroi (P. romeroi) is a saprophytic fungus widely distributed in the environment; it can be found on wood and in plants. (1) The fungal spores of P. romeroi can be inoculated into deeper tissues by trauma, (2, 3) and are a rare cause of skin and subcutaneous tissue infections. Herein, we report Singapore's first case of P. romeroi infection involving a 55-year-old renal transplant recipient who developed a chronic necrotising granulomatous skin lesion. The challenges involved in the diagnosis and treatment of this uncommon disease is discussed in this report.
CA S E R EPO RT
A 55-year-old Chinese man presented to our institution with a slow growing, painless nodular lesion on his left posterior thigh. One year before the current presentation, the patient had undergone a living related donor renal transplantation.
For the transplantation, the patient received cyclosporine and thymoglobulin at induction, followed by maintenance immunosuppressive therapy with prednisolone 10 mg once daily, mycophenolate mofetil 250 mg twice daily, and cyclosporin 45 mg once daily. He had an uneventful postoperative recovery, and his transplanted kidney was found to be functioning well with no signs of rejection during follow-up.
He did not have diabetes mellitus or a medical history of note, and he denied any history of trauma, soil exposure or participation in gardening activities. Throughout that one year (from renal transplantation to the current presentation), the patient did not show any systemic symptoms and his inflammatory markers (white cell count and C-reactive protein)
were unremarkable. For his current presentation, the patient underwent ultrasonography of his left posterior thigh lesion, which revealed a thick-walled cystic mass. Histologic examination of the biopsied specimen showed necrotising granulomatous inflammation with fungal hyphae.
The thigh lesion recurred and progressed despite repeated attempts at complete surgical excision over a one-year period. In vitro antifungal susceptibility test was performed, but the results were inconclusive because the fungus failed to grow well in the susceptibility testing medium. Nevertheless, the interpretation of the susceptibility data of this unusual mould (P. romeroi) would be difficult because there was no standardised susceptibility data for moulds other than those of the Aspergillus genus. The patient was started empirically on itraconazole syrup 200 mg twice daily for a period of two years. There was gradual reduction of the lesion size and the lesion remained quiescent in those two years. Throughout the course of treatment, itraconazole serum level was not monitored due to the unavailability of the test at our centre. it is usually due to the introduction of fungal spores into deeper tissues by trauma, typically in exposed areas of the body. (3, 6, 7) P. romeroi has been isolated from cases of mycetoma, in which the fungi is characterised by the production of soft, irregular, black grains with a subhyaline center. (2, 4, 5) In those cases, the lesions were found to develop slowly after trauma and were typically localised to cutaneous and subcutaneous tissues.
Subcutaneous abscess due to

In cases of Pyrenochaeta infection, inflammatory markers
including leucocyte count and C-reactive protein are typically normal, (1, 7) as was seen in the present case. Most of the reported cases of P. romeroi infection involved mycetoma patients with a history of residence in India, Senegal or Pakistan. (7) (8) (9) Patients included healthy individuals, renal transplant recipients on immunosuppressive therapy, and acute lymphoblastic leukaemia patients on chemotherapy. (1,7)
P. romeroi has been reported to be resistant, with high MICs, to amphotericin B, fluconazole and caspofungin, (7, 8) and the effect of voriconazole was reported to be variable. (1, (6) (7) (8) Itraconazole was shown to be potent by Badali et al, but resistant by Cerar et al. (7, 8) Since the susceptibility test was unsuccessful in the present case, the choice of itraconazole was empirical.
Our patient responded to the treatment with itraconazole after prolonged therapy, but relapsed during dose reduction.
Khan et al and Badali et al reported two cases of subcutaneous infections that were successfully treated with surgical excision alone (i.e. without the use of antifungals). (6, 7) Other reports used surgical debridement followed by prolonged use of triazole. (1, 8) In a case series of patients with phaeohyphomycosis, itraconazole was demonstrated to be effective in some patients. (1) The present case adds to the evidence provided by the aforementioned case series, (10) which found that prolonged itraconazole therapy leads to improvement in those who fail to respond to surgical treatment alone. In the present case, the failure to respond surgical treatment alone may be the result of our patient's immunocompromised state.
There are several reasons as to why the isolation of P. romeroi in our patient is likely to be clinically significant and unlikely due to colonisation or contamination. Firstly, the fungus was grown from the lesion from the left thigh on five occasions, and all specimens were obtained by surgical biopsy or needle aspiration of the lesion. Although the fungus was non-sporulating and a diagnosis could not be made based on the fungal cultures, subsequent molecular diagnostic sequencing of three of the five isolates, performed on separate occasions, all yielded P. romeroi. Finally, the lesion decreased in size only after the patient was treated with itraconazole, and this reduction in size was reversed when the dose of itraconazole was reduced.
In post-transplant or immunocompromised patients with skin and soft tissue infections, it is imperative to consider a fungal aetiology. An early diagnosis may be possible via a biopsy of the lesion. P. romeroi infection is rare, difficult to identify, and knowledge about its antifungal susceptibility is limited.
Although treatment of eumycetoma is mainly surgical, we recommend that additional antifungal therapy and close follow-up be practised when immunosuppressed patients are involved. This is so that further progression of the infection and recurrence of this invasive disease are prevented. In the present case, itraconazole appears to be effective against eumycetoma that is caused by P. romeroi infection.
